...
首页> 外文期刊>Japanese journal of clinical oncology. >Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with Cytosine arabinoside and hydrocortisone.
【24h】

Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with Cytosine arabinoside and hydrocortisone.

机译:实体瘤软脑膜癌的鞘内化疗比较:甲氨蝶呤与甲氨蝶呤联合胞嘧啶阿拉伯糖苷和氢化可的松的比较。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVE: To compare the efficacy of intrathecal methotrexate single therapy with three-drug combination therapy in patients with leptomeningeal carcinomatosis. METHODS: Fifty-five patients who had pathologically proven leptomeningeal carcinomatosis of a solid tumor were evaluated in terms of pathological response. Group M (n = 29) received methotrexate 15 mg and group MHA (n = 26) received methotrexate 15 mg, hydrocortisone 15 mg/m(2) and ara-C 30 mg/m(2) twice a week intrathecally until a cytological response was obtained. RESULTS: Primary sites of the tumor were the lung (n = 33), breast (n = 13) and stomach (n = 5). The pathology of 45 patients was adenocarcinoma. The cytological response rate to intrathecal chemotherapy was significantly higher in the MHA group than in the M group (38.5 vs 13.8%, P = 0.036). The median survival was 18.6 weeks in the MHA arm and 10.4 weeks in the M arm (P = 0.029). CONCLUSION: Combination intrathecal chemotherapy with methotrexate, cytosine arabinoside and hydrocortisone showed more favorable effects than methotrexate single therapy for leptomeningeal carcinomatosis in solid tumors.
机译:目的:比较鞘内甲氨蝶呤单药治疗与三药联合治疗对软脑膜癌的疗效。方法:对55例经病理证实为实体瘤的小脑脑膜癌的患者进行了病理学评估。 M组(n = 29)每周两次鞘内注射甲氨蝶呤15 mg,MHA组(n = 26)接受甲氨蝶呤15 mg,氢化可的松15 mg / m(2)和ara-C 30 mg / m(2)每周一次,直至细胞学检查获得了回应。结果:肿瘤的主要部位是肺(n = 33),乳房(n = 13)和胃(n = 5)。 45例患者的病理为腺癌。 MHA组对鞘内化疗的细胞学应答率显着高于M组(38.5 vs 13.8%,P = 0.036)。 MHA组中位生存期为18.6周,M组中位生存期为10.4周(P = 0.029)。结论:鞘内化疗联合甲氨蝶呤,胞嘧啶阿拉伯糖苷和氢化可的松对实体瘤软脑膜癌的治疗效果优于甲氨蝶呤单药治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号